Literature DB >> 17949302

Resistance mechanism against fluoroquinolones in Mycoplasma hyopneumoniae field isolates.

J Vicca1, D Maes, T Stakenborg, P Butaye, F Minion, J Peeters, A de Kruif, A Decostere, F Haesebrouck.   

Abstract

The quinolone resistance-determining regions (QRDR) of gyrA, gyrB, parC, and parE of ten Mycoplasma hyopneumoniae field isolates that were either sensitive (5) or resistant (5) to the fluoroquinolones flumequine and enrofloxacin were characterized. In all five resistant isolates, one point mutation (C --> A) in parC was found, resulting in an amino acid change from serine to tyrosine at position 80 (Escherichia coli numbering). For four of these isolates, this was the only mutation found. These isolates had a minimum inhibitory concentration (MIC) of enrofloxacin of 0.5 microg/ml, whereas for sensitive isolates the MIC of enrofloxacin was < or =0.06 microg/ml. One resistant isolate (Mh 20) had an extra mutation (C --> T) in gyrA resulting in an amino acid change from alanine to valine at position 83 (E. coli numbering), leading to a further increase in the MIC of enrofloxacin (>1 microg/ml). No mutations resulting in an amino acid change were detected in the QRDR of the gyrB and parE genes of the selected isolates. This is the first description of the mechanism of stepwise resistance against fluoroquinolones in M. hyopneumoniae.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17949302     DOI: 10.1089/mdr.2007.716

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  8 in total

1.  Rapid detection of a point mutation in the parC gene associated with decreased susceptibility to fluoroquinolones in Mycoplasma bovis.

Authors:  I Lysnyansky; I Mikula; I Gerchman; S Levisohn
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

2.  Characterization of Mutations in DNA Gyrase and Topoisomerase IV in Field Strains and In Vitro Selected Quinolone-Resistant Mycoplasma hyorhinis Mutants.

Authors:  Jun Li; Yanna Wei; Jia Wang; Yao Li; Guoqing Shao; Zhixin Feng; Qiyan Xiong
Journal:  Antibiotics (Basel)       Date:  2022-04-07

3.  Molecular characterization of acquired enrofloxacin resistance in Mycoplasma synoviae field isolates.

Authors:  I Lysnyansky; I Gerchman; I Mikula; F Gobbo; S Catania; S Levisohn
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

4.  Antibiotic susceptibility testing of Mycoplasma hyopneumoniae field isolates from Central Europe for fifteen antibiotics by microbroth dilution method.

Authors:  Orsolya Felde; Zsuzsa Kreizinger; Kinga Mária Sulyok; Veronika Hrivnák; Krisztián Kiss; Ákos Jerzsele; Imre Biksi; Miklós Gyuranecz
Journal:  PLoS One       Date:  2018-12-11       Impact factor: 3.240

5.  Antibiotic resistance of Mycoplasma Synoviae strains isolated in China from 2016 to 2019.

Authors:  Xiaorong Zhang; Mengjiao Guo; Di Xie; Yang Chen; Chengcheng Zhang; Yongzhong Cao; Yantao Wu
Journal:  BMC Vet Res       Date:  2022-01-03       Impact factor: 2.741

Review 6.  Mycoplasma bovis: Mechanisms of Resistance and Trends in Antimicrobial Susceptibility.

Authors:  Inna Lysnyansky; Roger D Ayling
Journal:  Front Microbiol       Date:  2016-04-27       Impact factor: 5.640

7.  Analysis of the mutant selection window and killing of Mycoplasma hyopneumoniae for doxycycline, tylosin, danofloxacin, tiamulin, and valnemulin.

Authors:  Zilong Huang; Chunxiao Mao; Yanzhe Wei; Xiaoyan Gu; Qinren Cai; Xiangguang Shen; Huanzhong Ding
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

Review 8.  Genomic Variability and Post-translational Protein Processing Enhance the Immune Evasion of Mycoplasma hyopneumoniae and Its Interaction With the Porcine Immune System.

Authors:  Gaojian Li; Enoch Obeng; Jinqi Shu; Jianhong Shu; Jian Chen; Yuehong Wu; Yulong He
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.